Haematologica

Haematologica www.haematologica.org publishes novel findings in basic, clinical and translational hematology research. Impact Factor (JCR) 7.116 (7th of 76)

Haematologica/The Hematology Journal (pISSN: 0390-6078, eISSN: 1592-8721, NLM ID: 0417435) publishes peer-reviewed papers across all areas of experimental and clinical hematology. The journal is owned by a non-profit organization, the Ferrata Storti Foundation, and serves the scientific community strictly following the International Committee of Medical Journal Editors (ICMJE, www.icmje.org) recom

mendations on publication ethics policies for medical journals. Haematologica was founded in 1920 by Adolfo Ferrata

A dual TKI strategy in blast-phase CMLBlast-phase chronic myeloid leukemia remains a major therapeutic challenge, partic...
29/04/2026

A dual TKI strategy in blast-phase CML
Blast-phase chronic myeloid leukemia remains a major therapeutic challenge, particularly after resistance to multiple tyrosine kinase inhibitors. This case report explores the combined use of asciminib and olverembatinib, addressing an emerging strategy targeting distinct BCR-ABL1 inhibitory mechanisms in advanced-phase disease.
https://haematologica.org/article/view/13045

CAR T cells in primary CNS lymphomaTreatment options for primary central nervous system (CNS) lymphoma remain limited, p...
27/04/2026

CAR T cells in primary CNS lymphoma
Treatment options for primary central nervous system (CNS) lymphoma remain limited, particularly in relapsed or refractory disease. This case report explores the activity and CNS trafficking of tandem CD20/CD19 CAR T cells (zamtocabtagene autoleucel), addressing key questions about cellular therapy in CNS lymphoma and the potential role of dual-target CAR T strategies.
https://haematologica.org/article/view/12949

Teclistamab, a bispecific antody, was recently approved for use in relapsed/refractory multiple myeloma, following the r...
25/04/2026

Teclistamab, a bispecific antody, was recently approved for use in relapsed/refractory multiple myeloma, following the results of a pivotal phase I-II study (MajesTEC-1). Is teclistamab effective in other monoclonal gammopathies of clinical significance? Find here the case of 73-year-old man with a 20-year history of heavily treated relapsed/refractory POEMS syndrome who achieved a rapid and durable complete remission 6 months after his last injection of teclistamab.
https://haematologica.org/article/view/12152

How should we manage primary mediastinal B-cell lymphoma patients with relapsed/refractory disease after frontline DA-EP...
23/04/2026

How should we manage primary mediastinal B-cell lymphoma patients with relapsed/refractory disease after frontline DA-EPOCH-R? A retrospective review of 107 patients helps to find answers.
https://haematologica.org/article/view/12964

Neutrophils, the most abundant immune cells in human blood, play a pivotal role in host defense against invading pathoge...
21/04/2026

Neutrophils, the most abundant immune cells in human blood, play a pivotal role in host defense against invading pathogens, but are also capable of inflicting tissue damage, a common feature of diverse inflammatory pathologies. Therefore, blocking neutrophil influx has been considered an interesting therapeutic concept in diseases with overwhelming neutrophil responses. Using several in vivo and in vitro approaches a new study investigates the mode of action of ladarixin, a dual non-competitive inhibitor of chemokine receptors CXCR1 and CXCR2, in blocking neutrophil recruitment during inflammation.
https://haematologica.org/article/view/12235

The bone marrow microenvironment plays a central role in hematopoiesis and hematologic diseases. A new study investigate...
19/04/2026

The bone marrow microenvironment plays a central role in hematopoiesis and hematologic diseases. A new study investigates how HES1 regulates mesenchymal stromal cell function and inflammatory signaling, exploring a novel pathway that may shape hematopoietic homeostasis and disease biology.
https://haematologica.org/article/view/12907

About long-term outcomes with triplet therapy in FLT3-mutated acute myeloid leukemia. Triplet regimens combining hypomet...
17/04/2026

About long-term outcomes with triplet therapy in FLT3-mutated acute myeloid leukemia.
Triplet regimens combining hypomethylating agents, venetoclax, and FLT3 inhibitors are increasingly used in newly diagnosed FLT3-mutated acute myeloid leukemia (AML). Read results of the study examining long-term outcomes and patterns of relapse with frontline triplet therapy. A key question in the evolving management of FLT3-mutated AML.
https://haematologica.org/article/view/12909

Metabolic reprogramming in acute myeloid leukemia.Metabolic adaptation is emerging as a key feature in acute myeloid leu...
15/04/2026

Metabolic reprogramming in acute myeloid leukemia.
Metabolic adaptation is emerging as a key feature in acute myeloid leukemia biology. A new study investigates the role of SLC25A1 in mitochondrial and fatty acid metabolism, exploring how metabolic reprogramming may contribute to leukemia progression and identifying potential vulnerabilities for future therapeutic strategies.
https://haematologica.org/article/view/12250

The complete blood count: too much information?From manual cell counting to advanced automated analyzers, the complete b...
13/04/2026

The complete blood count: too much information?
From manual cell counting to advanced automated analyzers, the complete blood count (CBC) has evolved into one of the most widely used laboratory tests in medicine. But has increasing technological sophistication improved clinical utility – or added complexity? This perspective revisits the evolution of the CBC and examines whether current practice may benefit from rethinking which parameters truly matter for patients’ care.
https://haematologica.org/article/view/13039

Spotlight Review Article: Biomarkers in mantle cell lymphoma in the era of targeted therapies. The treatment landscape o...
11/04/2026

Spotlight Review Article: Biomarkers in mantle cell lymphoma in the era of targeted therapies.
The treatment landscape of mantle cell lymphoma continues to evolve with the introduction of targeted agents. This review examines emerging biomarkers that may refine risk stratification, guide treatment selection, and inform disease monitoring, addressing key challenges in personalized management of mantle cell lymphoma.
https://haematologica.org/article/view/12980

Review Article: Choosing JAK inhibitors in complex myelofibrosis scenarios. Selecting the most appropriate JAK inhibitor...
09/04/2026

Review Article: Choosing JAK inhibitors in complex myelofibrosis scenarios.
Selecting the most appropriate JAK inhibitor for patients with myelofibrosis can be challenging, particularly in the presence of cytopenias, prior treatment exposure, or comorbidities. This review examines key clinical scenarios and discusses how therapeutic decisions may be tailored in real-world practice, addressing an increasingly relevant question in modern myelofibrosis management.
https://haematologica.org/article/view/13005

Indirizzo

Via Giuseppe Belli 4
Pavia
27100

Orario di apertura

Lunedì 09:00 - 18:00
Martedì 09:00 - 18:00
Mercoledì 09:00 - 18:00
Giovedì 09:00 - 18:00
Venerdì 09:00 - 18:00

Telefono

+39038227129

Sito Web

Notifiche

Lasciando la tua email puoi essere il primo a sapere quando Haematologica pubblica notizie e promozioni. Il tuo indirizzo email non verrà utilizzato per nessun altro scopo e potrai annullare l'iscrizione in qualsiasi momento.

Contatta Lo Studio

Invia un messaggio a Haematologica:

Scelte rapide

In evidenza

Condividi